J.L. Bainbridge & Co’s Pfizer PFE Stock Holding History

J.L. Bainbridge & Co’s Portfolio PFE Stock Details PFE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q4	–	Sell	-6,040	Closed	-$200K	–	89
2023 Q3	$200K	Buy	6,040 +98	+2%	+$3.47K	0.03%	75
2023 Q2	$218K	Buy	5,942 +3	+0.1%	+$117	0.03%	70
2023 Q1	$242K	Sell	5,939 -5	-0.1%	-$216	0.03%	62
2022 Q4	$305K	Buy	5,944 +175	+3%	+$8.39K	0.05%	52
2022 Q3	$252K	Buy	5,769 +1,002	+21%	+$48.7K	0.04%	56
2022 Q2	$250K	Buy	4,767 +251	+6%	+$12.8K	0.04%	61
2022 Q1	$234K	Sell	4,516 -399	-8%	-$20.7K	0.03%	77
2021 Q4	$290K	Buy	4,915 +118	+2%	+$5.85K	0.03%	68
2021 Q3	$206K	Buy	+4,797	New	+$213K	0.02%	91
2020 Q1	–	Sell	-6,269	Closed	-$233K	–	82
2019 Q4	$233K	Buy	6,269 +159	+3%	+$5.66K	0.03%	75
2019 Q3	$208K	Buy	6,110 +322	+6%	+$11.7K	0.03%	69
2019 Q2	$238K	Sell	5,788 -2,013	-26%	-$79.9K	0.04%	60
2019 Q1	$308K	Sell	7,801 -1,692	-18%	-$67.8K	0.05%	45
2018 Q4	$393K	Buy	9,493 +7	+0.1%	+$291	0.07%	42
2018 Q3	$397K	Buy	+9,486	New	+$365K	0.05%	43

Other funds holding PFE

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

J.L. Bainbridge & Co's PFE Position: Q4 2023 in Review

J.L. Bainbridge & Co sold out of Pfizer (PFE) in Q4 2023, closing a stake of 6,040 shares — an estimated $200K sold.

J.L. Bainbridge & Co first reported a position in PFE in Q3 2018 and held it in 15 quarters. The position peaked at $397K in Q3 2018. 2,935 funds tracked by Wall St. Rank hold PFE as of Q4 2023.

J.L. Bainbridge & Co reported no remaining Pfizer position as of Q4 2023 after selling out during the quarter.
J.L. Bainbridge & Co sold 6,040 Pfizer shares in Q4 2023, an estimated $200K.
J.L. Bainbridge & Co first reported a position in Pfizer in Q3 2018 and held it in 15 quarters.
J.L. Bainbridge & Co's Pfizer position peaked at $397K in Q3 2018.
2,935 funds tracked by Wall St. Rank held Pfizer as of Q4 2023.

Based on J.L. Bainbridge & Co's 13F filing for Q4 2023, filed 12 Feb 2024.